A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer-Reference-Cited by-同舟云学术

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

Published:2014-05-29 Issue:2 Volume:74 Page:229-238
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Masuda N.,Higaki K.,Takano T.,Matsunami N.,Morimoto T.,Ohtani S.,Mizutani M.,Miyamoto T.,Kuroi K.,Ohno S.,Morita S.,Toi M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2492-y.pdf

Reference47 articles.

1. Iwase H, Kurebayashi J, Tsuda H et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118–124

2. Japanese Breast Cancer Society (2004) Investigative Report on Registration of Breast Cancer Patients in Japan [in Japanese]. No. 35

3. Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20:40–46

4. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109:1721–1728

5. Liedtke C, Maouni D, Hoss KR et al (2008) Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geraniol suppresses tumour growth and enhances chemosensitivity of 5-fluorouracil on breast carcinoma in mice: involvement of miR-21/PTEN signalling;Journal of Pharmacy and Pharmacology;2023-06-28

2. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy;Immunotherapy;2023-04

3. Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies;Neoplasia;2022-10

4. Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies;2022-02-10

5. Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach;Scientific Reports;2021-11-02